Unravelling the intricate dynamics of the PRP19‐CDC5L complex in the context of AD pathology could pave the way for innovative therapeutic interventions aimed at modulating splicing irregularities [39, 40, 41]. This evidence concerns the gene CDC5L and Alzheimer disease.